메뉴 건너뛰기




Volumn 50, Issue 2-3, 2011, Pages 294-302

The CSPG4-specific monoclonal antibody enhances and prolongs the effects of the BRAF inhibitor in melanoma cells

Author keywords

BRAF inhibitor PLX4032; BRAF inhibitor resistance; CSPG4 specific mAb; Melanoma; Signaling pathways

Indexed keywords

B RAF KINASE; CHONDROITIN SULFATE PROTEOGLYCAN 4; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 225.28; PROTEOGLYCAN; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; UNCLASSIFIED DRUG; VEMURAFENIB;

EID: 79961167816     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-011-8232-z     Document Type: Article
Times cited : (34)

References (34)
  • 1
    • 84857017872 scopus 로고    scopus 로고
    • Epidemiology of invasive cutaneous melanoma
    • RM MacKie A Hauschild AM Eggermont 2009 Epidemiology of invasive cutaneous melanoma Ann Oncol 20 Suppl 6 1 7
    • (2009) Ann Oncol , vol.20 , Issue.SUPPL. 6 , pp. 1-7
    • MacKie, R.M.1    Hauschild, A.2    Eggermont, A.M.3
  • 2
    • 0036788419 scopus 로고    scopus 로고
    • Radiation therapy of malignant melanoma
    • 12380058 10.1016/S0733-8635(02)00029-3
    • JS Cooper 2002 Radiation therapy of malignant melanoma Dermatol Clin 20 713 716 12380058 10.1016/S0733-8635(02)00029-3
    • (2002) Dermatol Clin , vol.20 , pp. 713-716
    • Cooper, J.S.1
  • 3
    • 0037398451 scopus 로고    scopus 로고
    • World Health Organization experience in the treatment of melanoma
    • DOI 10.1016/S0039-6109(02)00089-0, PII S0039610902000890
    • N Cascinelli M Santinami A Maurichi R Patuzzo E Pennacchioli 2003 World Health Organization experience in the treatment of melanoma Surg Clin North Am 83 405 416 12744616 10.1016/S0039-6109(02)00089-0 (Pubitemid 36514816)
    • (2003) Surgical Clinics of North America , vol.83 , Issue.2 , pp. 405-416
    • Cascinelli, N.1    Santinami, M.2    Maurichi, A.3    Patuzzo, R.4    Pennacchioli, E.5
  • 4
    • 77956030786 scopus 로고    scopus 로고
    • Inhibition of mutated, activated BRAF in metastatic melanoma
    • 20818844 10.1056/NEJMoa1002011 1:CAS:528:DC%2BC3cXhtVyksb3M
    • KT Flaherty I Puzanov KB Kim, et al. 2010 Inhibition of mutated, activated BRAF in metastatic melanoma N Engl J Med 363 809 819 20818844 10.1056/NEJMoa1002011 1:CAS:528:DC%2BC3cXhtVyksb3M
    • (2010) N Engl J Med , vol.363 , pp. 809-819
    • Flaherty, K.T.1    Puzanov, I.2    Kim, K.B.3
  • 5
    • 78249254899 scopus 로고    scopus 로고
    • BRAF, a target in melanoma: Implications for solid tumor drug development
    • 20629085 10.1002/cncr.25261 1:CAS:528:DC%2BC3cXhsVymtL7L
    • KT Flaherty G McArthur 2010 BRAF, a target in melanoma: implications for solid tumor drug development Cancer 116 4902 4913 20629085 10.1002/cncr.25261 1:CAS:528:DC%2BC3cXhsVymtL7L
    • (2010) Cancer , vol.116 , pp. 4902-4913
    • Flaherty, K.T.1    McArthur, G.2
  • 6
    • 77950672269 scopus 로고    scopus 로고
    • Targeting multiple kinase pathways: A change in paradigm
    • 20215532 10.1158/1078-0432.CCR-09-3182 1:CAS:528:DC%2BC3cXktFygu7w%3D
    • L Gossage T Eisen 2010 Targeting multiple kinase pathways: a change in paradigm Clin Cancer Res 16 1973 1978 20215532 10.1158/1078-0432.CCR-09-3182 1:CAS:528:DC%2BC3cXktFygu7w%3D
    • (2010) Clin Cancer Res , vol.16 , pp. 1973-1978
    • Gossage, L.1    Eisen, T.2
  • 7
    • 59649123810 scopus 로고    scopus 로고
    • Integrating BRAF/MEK inhibitors into combination therapy for melanoma
    • 19156138 10.1038/sj.bjc.6604891 1:CAS:528:DC%2BD1MXhsFektr4%3D
    • KS Smalley KT Flaherty 2009 Integrating BRAF/MEK inhibitors into combination therapy for melanoma Br J Cancer 100 431 435 19156138 10.1038/sj.bjc.6604891 1:CAS:528:DC%2BD1MXhsFektr4%3D
    • (2009) Br J Cancer , vol.100 , pp. 431-435
    • Smalley, K.S.1    Flaherty, K.T.2
  • 8
    • 49649118852 scopus 로고    scopus 로고
    • Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma
    • 18559533 10.1158/0008-5472.CAN-07-6787 1:CAS:528:DC%2BD1cXnt1ejsbs%3D
    • C Montagut SV Sharma T Shioda, et al. 2008 Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma Cancer Res 68 4853 4861 18559533 10.1158/0008-5472.CAN-07-6787 1:CAS:528:DC%2BD1cXnt1ejsbs%3D
    • (2008) Cancer Res , vol.68 , pp. 4853-4861
    • Montagut, C.1    Sharma, S.V.2    Shioda, T.3
  • 9
    • 69949151386 scopus 로고    scopus 로고
    • Factors underlying sensitivity of cancers to small-molecule kinase inhibitors
    • 19629074 10.1038/nrd2871 1:CAS:528:DC%2BD1MXovFylur4%3D
    • PA Janne N Gray J Settleman 2009 Factors underlying sensitivity of cancers to small-molecule kinase inhibitors Nat Rev Drug Discov 8 709 723 19629074 10.1038/nrd2871 1:CAS:528:DC%2BD1MXovFylur4%3D
    • (2009) Nat Rev Drug Discov , vol.8 , pp. 709-723
    • Janne, P.A.1    Gray, N.2    Settleman, J.3
  • 10
    • 77949732073 scopus 로고    scopus 로고
    • RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
    • 20179705 10.1038/nature08902 1:CAS:528:DC%2BC3cXjsFWjsrs%3D
    • PI Poulikakos C Zhang G Bollag KM Shokat N Rosen 2010 RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF Nature 464 427 430 20179705 10.1038/nature08902 1:CAS:528:DC%2BC3cXjsFWjsrs%3D
    • (2010) Nature , vol.464 , pp. 427-430
    • Poulikakos, P.I.1    Zhang, C.2    Bollag, G.3    Shokat, K.M.4    Rosen, N.5
  • 11
    • 78650303507 scopus 로고    scopus 로고
    • Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
    • 21107323 10.1038/nature09626 1:CAS:528:DC%2BC3cXhsVOrsbjI
    • R Nazarian H Shi Q Wang, et al. 2010 Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation Nature 468 973 977 21107323 10.1038/nature09626 1:CAS:528:DC%2BC3cXhsVOrsbjI
    • (2010) Nature , vol.468 , pp. 973-977
    • Nazarian, R.1    Shi, H.2    Wang, Q.3
  • 12
    • 78650309875 scopus 로고    scopus 로고
    • COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
    • 21107320 10.1038/nature09627 1:CAS:528:DC%2BC3cXhsVOrsLvP
    • CM Johannessen JS Boehm SY Kim, et al. 2010 COT drives resistance to RAF inhibition through MAP kinase pathway reactivation Nature 468 968 972 21107320 10.1038/nature09627 1:CAS:528:DC%2BC3cXhsVOrsLvP
    • (2010) Nature , vol.468 , pp. 968-972
    • Johannessen, C.M.1    Boehm, J.S.2    Kim, S.Y.3
  • 13
    • 74949136580 scopus 로고    scopus 로고
    • Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies
    • 20028761 10.1158/1078-0432.CCR-09-2345 1:CAS:528:DC%2BC3cXotFyn
    • M Campoli R Ferris S Ferrone X Wang 2010 Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies Clin Cancer Res 16 11 20 20028761 10.1158/1078-0432.CCR-09-2345 1:CAS:528:DC%2BC3cXotFyn
    • (2010) Clin Cancer Res , vol.16 , pp. 11-20
    • Campoli, M.1    Ferris, R.2    Ferrone, S.3    Wang, X.4
  • 14
    • 77957829001 scopus 로고    scopus 로고
    • CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer
    • 20852124 10.1093/jnci/djq343
    • X Wang T Osada Y Wang, et al. 2010 CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer J Natl Cancer Inst 102 1496 1512 20852124 10.1093/jnci/djq343
    • (2010) J Natl Cancer Inst , vol.102 , pp. 1496-1512
    • Wang, X.1    Osada, T.2    Wang, Y.3
  • 15
    • 77953496846 scopus 로고    scopus 로고
    • CSPG4 in cancer: Multiple roles
    • 20455858 10.2174/156652410791316977 1:CAS:528:DC%2BC3cXmsVamsbg%3D
    • X Wang Y Wang L Yu, et al. 2010 CSPG4 in cancer: multiple roles Curr Mol Med 10 419 429 20455858 10.2174/156652410791316977 1:CAS:528: DC%2BC3cXmsVamsbg%3D
    • (2010) Curr Mol Med , vol.10 , pp. 419-429
    • Wang, X.1    Wang, Y.2    Yu, L.3
  • 17
    • 70350227318 scopus 로고    scopus 로고
    • Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to-mesenchymal transition
    • 19738072 10.1158/0008-5472.CAN-08-4626 1:CAS:528:DC%2BD1MXht1Skt7rK
    • J Yang MA Price GY Li, et al. 2009 Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to- mesenchymal transition Cancer Res 69 7538 7547 19738072 10.1158/0008-5472.CAN- 08-4626 1:CAS:528:DC%2BD1MXht1Skt7rK
    • (2009) Cancer Res , vol.69 , pp. 7538-7547
    • Yang, J.1    Price, M.A.2    Li, G.Y.3
  • 18
    • 9444251067 scopus 로고    scopus 로고
    • Integrin αv-mediated inactivation of p53 controls a MEK1-dependent melanoma cell survival pathway in three-dimensional collagen
    • DOI 10.1083/jcb.200404018
    • W Bao S Stromblad 2004 Integrin alphav-mediated inactivation of p53 controls a MEK1-dependent melanoma cell survival pathway in three-dimensional collagen J Cell Biol 167 745 756 15557124 10.1083/jcb.200404018 1:CAS:528:DC%2BD2cXhtVaqtb3P (Pubitemid 39565154)
    • (2004) Journal of Cell Biology , vol.167 , Issue.4 , pp. 745-756
    • Bao, W.1    Stromblad, S.2
  • 19
    • 48249126226 scopus 로고    scopus 로고
    • BRAFV600E mutations in malignant melanoma are associated with increased expressions of BAALC
    • Schrama D, Keller G, Houben R, et al. BRAFV600E mutations in malignant melanoma are associated with increased expressions of BAALC. J Carcinog 2008;7:1.
    • (2008) J Carcinog , vol.7 , pp. 1
    • Schrama, D.1    Keller, G.2    Houben, R.3
  • 20
    • 77950954465 scopus 로고    scopus 로고
    • Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032
    • Sondergaard JN, Nazarian R, Wang Q, et al. Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. J Transl Med 2010;8:39.
    • (2010) J Transl Med , vol.8 , pp. 39
    • Sondergaard, J.N.1    Nazarian, R.2    Wang, Q.3
  • 21
    • 77954376912 scopus 로고    scopus 로고
    • RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models
    • 20551065 10.1158/0008-5472.CAN-10-0646 1:CAS:528:DC%2BC3cXot1Wks7Y%3D
    • H Yang B Higgins K Kolinsky, et al. 2010 RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models Cancer Res 70 5518 5527 20551065 10.1158/0008-5472.CAN-10-0646 1:CAS:528:DC%2BC3cXot1Wks7Y%3D
    • (2010) Cancer Res , vol.70 , pp. 5518-5527
    • Yang, H.1    Higgins, B.2    Kolinsky, K.3
  • 22
    • 65249119397 scopus 로고    scopus 로고
    • Phosphorylated 4E-BP1 is associated with poor survival in melanoma
    • 19336517 10.1158/1078-0432.CCR-08-2336
    • KE O'Reilly M Warycha MA Davies, et al. 2009 Phosphorylated 4E-BP1 is associated with poor survival in melanoma Clin Cancer Res 15 2872 2878 19336517 10.1158/1078-0432.CCR-08-2336
    • (2009) Clin Cancer Res , vol.15 , pp. 2872-2878
    • O'Reilly, K.E.1    Warycha, M.2    Davies, M.A.3
  • 23
    • 66449103375 scopus 로고    scopus 로고
    • Structure and regulation of the versican promoter: The versican promoter is regulated by AP-1 and TCF transcription factors in invasive human melanoma cells
    • 19269971 10.1074/jbc.M807108200 1:CAS:528:DC%2BD1MXltVClsr4%3D
    • C Domenzain-Reyna D Hernandez L Miquel-Serra, et al. 2009 Structure and regulation of the versican promoter: the versican promoter is regulated by AP-1 and TCF transcription factors in invasive human melanoma cells J Biol Chem 284 12306 12317 19269971 10.1074/jbc.M807108200 1:CAS:528:DC%2BD1MXltVClsr4%3D
    • (2009) J Biol Chem , vol.284 , pp. 12306-12317
    • Domenzain-Reyna, C.1    Hernandez, D.2    Miquel-Serra, L.3
  • 24
    • 77956513286 scopus 로고    scopus 로고
    • Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
    • 20823850 10.1038/nature09454 1:CAS:528:DC%2BC3cXht1ajtbfK
    • G Bollag P Hirth J Tsai, et al. 2010 Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma Nature 467 596 599 20823850 10.1038/nature09454 1:CAS:528:DC%2BC3cXht1ajtbfK
    • (2010) Nature , vol.467 , pp. 596-599
    • Bollag, G.1    Hirth, P.2    Tsai, J.3
  • 25
    • 11144232998 scopus 로고    scopus 로고
    • Human high molecular weight-melanoma-associated antigen (HMW-MAA): A melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance
    • DOI 10.1615/CritRevImmunol.v24.i4.40
    • MR Campoli CC Chang T Kageshita X Wang JB McCarthy S Ferrone 2004 Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance Crit Rev Immunol 24 267 296 15588226 10.1615/CritRevImmunol.v24.i4. 40 1:CAS:528:DC%2BD2MXotFOksw%3D%3D (Pubitemid 40052428)
    • (2004) Critical Reviews in Immunology , vol.24 , Issue.4 , pp. 267-296
    • Campoli, M.R.1    Chang, C.-C.2    Kageshita, T.3    Wang, X.4    McCarthy, J.B.5    Ferrone, S.6
  • 26
    • 0024239488 scopus 로고
    • Syngeneic antiidiotypic monoclonal antibodies to the murine anti-HLA-DR,DP monoclonal antibody CR11-462
    • DOI 10.1016/0198-8859(88)90061-4
    • F Perosa S Ferrone 1988 Syngeneic antiidiotypic monoclonal antibodies to the murine anti-HLA-DR, DP monoclonal antibody CR11-462 Hum Immunol 23 255 269 3266207 10.1016/0198-8859(88)90061-4 1:STN:280:DyaL1M7nsVSmsQ%3D%3D (Pubitemid 19009573)
    • (1988) Human Immunology , vol.23 , Issue.4 , pp. 255-269
    • Perosa, F.1    Ferrrone, S.2
  • 27
    • 0024515896 scopus 로고
    • Purification of murine IgG monoclonal antibodies by precipitation with caprylic acid: Comparison with other methods of purification
    • M Temponi T Kageshita F Perosa R Ono H Okada S Ferrone 1989 Purification of murine IgG monoclonal antibodies by precipitation with caprylic acid: comparison with other methods of purification Hybridoma 8 85 95 2784406 10.1089/hyb.1989.8.85 1:CAS:528:DyaL1MXhvFSmt7o%3D (Pubitemid 19082761)
    • (1989) Hybridoma , vol.8 , Issue.1 , pp. 85-95
    • Temponi, M.1    Kageshita, T.2    Perosa, F.3    Ono, K.4    Okada, H.5    Ferrone, S.6
  • 28
    • 0031586337 scopus 로고    scopus 로고
    • A central segment of the NG2 proteoglycan is critical for the ability of glioma cells to bind and migrate toward type VI collagen
    • DOI 10.1006/excr.1997.3674
    • MA Burg A Nishiyama WB Stallcup 1997 A central segment of the NG2 proteoglycan is critical for the ability of glioma cells to bind and migrate toward type VI collagen Exp Cell Res 235 254 264 9281375 10.1006/excr.1997.3674 1:CAS:528:DyaK2sXlvVKgtLs%3D (Pubitemid 27381704)
    • (1997) Experimental Cell Research , vol.235 , Issue.1 , pp. 254-264
    • Burg, M.A.1    Nishiyama, A.2    Stallcup, W.B.3
  • 29
    • 0031685581 scopus 로고    scopus 로고
    • Expression of the NG2 proteoglycan enhances the growth and metastatic properties of melanoma cells
    • DOI 10.1002/(SICI)1097-4652(199 811)177:2<299::AID-JCP12>3.0.CO;2-5
    • MA Burg KA Grako WB Stallcup 1998 Expression of the NG2 proteoglycan enhances the growth and metastatic properties of melanoma cells J Cell Physiol 177 299 312 9766527 10.1002/(SICI)1097-4652(199811)177:2<299::AID-JCP12>3. 0.CO;2-5 1:CAS:528:DyaK1cXmsValt70%3D (Pubitemid 28452831)
    • (1998) Journal of Cellular Physiology , vol.177 , Issue.2 , pp. 299-312
    • Burg, M.A.1    Grako, K.A.2    Stallcup, W.B.3
  • 30
    • 77953276524 scopus 로고    scopus 로고
    • Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy
    • 20531415 10.1038/sj.bjc.6605714 1:CAS:528:DC%2BC3cXntFSnsrc%3D
    • KH Paraiso IV Fedorenko LP Cantini, et al. 2010 Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy Br J Cancer 102 1724 1730 20531415 10.1038/sj.bjc.6605714 1:CAS:528:DC%2BC3cXntFSnsrc%3D
    • (2010) Br J Cancer , vol.102 , pp. 1724-1730
    • Paraiso, K.H.1    Fedorenko, I.V.2    Cantini, L.P.3
  • 31
    • 77949354563 scopus 로고    scopus 로고
    • PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells
    • 20149136 10.1111/j.1755-148X.2010.00685.x 1:CAS:528:DC%2BC3cXltF2ls7s%3D
    • R Halaban W Zhang A Bacchiocchi, et al. 2010 PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells Pigment Cell Melanoma Res 23 190 200 20149136 10.1111/j.1755-148X.2010.00685.x 1:CAS:528:DC%2BC3cXltF2ls7s%3D
    • (2010) Pigment Cell Melanoma Res , vol.23 , pp. 190-200
    • Halaban, R.1    Zhang, W.2    Bacchiocchi, A.3
  • 32
    • 78650008177 scopus 로고    scopus 로고
    • Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3 K
    • 21156289 10.1016/j.ccr.2010.11.023 1:CAS:528:DC%2BC3cXhsFGhsbjJ
    • J Villanueva A Vultur JT Lee, et al. 2010 Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3 K Cancer Cell 18 683 695 21156289 10.1016/j.ccr.2010.11.023 1:CAS:528:DC%2BC3cXhsFGhsbjJ
    • (2010) Cancer Cell , vol.18 , pp. 683-695
    • Villanueva, J.1    Vultur, A.2    Lee, J.T.3
  • 33
    • 79961173275 scopus 로고    scopus 로고
    • [cited; Available from:
    • Flaherty K. 2011 [cited; Available from: http://www.dfhcc.harvard.edu/ news/news/article/4126/334/?PHPSESSID=c84186b744715f955d507b9356d0f3b2.
    • (2011)
    • Flaherty, K.1
  • 34
    • 0026584248 scopus 로고
    • Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: Induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma
    • 1731316 10.1073/pnas.89.2.466 1:STN:280:DyaK387hsFKrsQ%3D%3D
    • A Mittelman ZJ Chen H Yang GY Wong S Ferrone 1992 Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma Proc Natl Acad Sci USA 89 466 470 1731316 10.1073/pnas.89.2.466 1:STN:280:DyaK387hsFKrsQ%3D%3D
    • (1992) Proc Natl Acad Sci USA , vol.89 , pp. 466-470
    • Mittelman, A.1    Chen, Z.J.2    Yang, H.3    Wong, G.Y.4    Ferrone, S.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.